Chugai reveals internal restructuring

Chugai has reported an update of restructuring measures it is currently taking to maximise productivity at the company.

The firm’s director and executive vice-president Ryuzo Kodama will now also head up its financial supervisory division, specifically in the areas of corporate communications and purchasing.

Tatsumi Yamazaki, the executive vice-president of portfolio management, will oversee corporate regulatory compliance and quality assurance, as well as research, clinical development and drug safety.

Current senior vice-president of lifecycle management and marketing Tatsuro Kosaka has been appointed a director and the new executive vice-president of sales.

The changes will be effective from March 25th.

In other Takeda news, the organisation reported this week that Mepact (mifamurtide), its treatment for osteosarcoma, has been made commercially available in the EU.